Research on programmed-death 1 (PD-1) found on T cells and its receptor, programmed-death ligand 1 (PD-L1), found in varying levels on tumor is a central topic in immunotherapy.
Archive | Of Interest
Soluble PD-1 Is a Potential Biomarker in Metastatic Melanoma in Patients Treated With Autologous Vaccines
Posted in Melanoma News, Health Professionals, Of Interest
Single-Cell Level Variability May Help Predict Responses to BRAF Inhibitors in Melanoma
New targeted therapy options, such as BRAF and MEK inhibitors, offer advanced treatment for patients with melanoma; however, genetic variability often means that patients will have different therapeutic responses.
Posted in Melanoma News, Health Professionals, Of Interest
Enter the exosome: WVU researcher studies how cancer and immune cells communicate
Cells can’t text each other the way we can, but they can still communicate.
Posted in Melanoma News, Health Professionals, Of Interest
Moffitt Researchers Identify a Mechanism Controlling Tumor Cell Recognition by Immune Cells
TAMPA, Fla. – Immunotherapy has become a standard treatment approach for several types of cancer, including melanoma
Posted in Melanoma News, Health Professionals, Of Interest
